Surprisingly, although the high-risk patients’ background, the relapse rate was significantly lower than the historical control group, suggesting that adoptive transfer of Tregs followed by Tcons and CD34+ stem cells as acute GVHD prophylaxis strategy suppress GVHD without abrogating the GVT effect in a human setting. Here, CD34 is linked to graft versus host disease.